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Background: Infections due to Burkholderia cepacia complex (Bcc) strains increase morbidity and mortality in cystic fibrosis (CF). Some
transplant centres reject Bcc infected patients. We reviewed the results in patients treated with i.v temocillin.
Methods: Twenty-three patients who received 38 courses of temocillin (1988–1998) were identified from the CF database at Royal
Brompton Hospital. In three patients’ data were inadequate; therefore analysis was done in 20. Outcome was measured as improvement,
deterioration or no change (compared to admission) in the following categories: clinical (temperature, dyspnoea, sputum volume, chest pain),
physiological (FEV1, FVC, oxygen saturation) and inflammatory markers (WBC, ESR, CRP). Patients who improved in two categories were
classified as having improved. Antibiotic sensitivities and outcome were recorded.
Results: In 18 of 32 courses (56.25%) improvement occurred. The organism (Bcc) in eight patients’ sputum became resistant (three died).
The antibiotics was changed in five patients with Bcc strains sensitive to temocillin because of no improvement and one patient due to allergy
(rash). The average time to the next i.v antibiotic was 41 days. Eight patients died (in three the Bcc strain was resistant to temocillin).
Fourteen patients with Bcc were transplanted and eight patients survived. Another patient who developed Bcc infection post-operatively,
failing to respond to temocillin.
Conclusions: These results suggest the potential benefit of i.v temocillin in CF patients with Bcc for exacerbations and at the time of
transplantation.
D 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Temocillin; Burkholderia cepacia complex; Cystic fibrosis1. Introduction
Burkholderia cepacia is a highly virulent organism, in
certain patients with cystic fibrosis [1]. Most B. cepacia
complex isolates are resistant to many, or all of the
antibacterial agents commonly used in cystic fibrosis (CF),
and selection of appropriate antibiotics for treatment of
pulmonary exacerbations is therefore difficult. One report
has shown that the overall proportional hazard for death is
substantially enhanced if a CF patient is infected with B.
cepacia (3.22) or Pseudomonas aeruginosa (2.07), com-
pared with those infected with neither (1.00) [2].1569-1993/$ - see front matter D 2006 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2005.12.005
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E-mail address: s.hockley@ic.ac.uk (M.E. Hodson).Temocillin is a non-toxic and well tolerated antibiotic,
which fails to induce h-lactamase production; it therefore
does not antagonise other agents given concurrently for P.
aeruginosa infection. In a recent study evaluating the
activities of meropenem, imipenem, temocillin, piperacillin,
and ceftazidime by MICs for 66 genotypically characterized
Bcc isolates obtained from the sputum of CF patients,
temocillin was one of the most active h-lactam agents [3].
Preliminary data from our unit [4] indicated that temocillin
may be of benefit in the treatment of B. cepacia complex.
This retrospective study adds a further 10 years of
experience with temocillin, a h-lactamase stable antibiotic,
as first and second line therapy for pulmonary exacerbations
due to Bcc in 23 patients with CF.
Some transplant centres will not accept patients with Bcc.
We are also able to present data detailing our experience of5 (2006) 121 – 124ed by Elsevier B.V. All rights reserved.
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were treated with temocillin post-operatively.
2. Methods
Between 1988 and 1998, a total of 38 courses of
intravenous temocillin were given in combination with an
intravenous aminoglycoside to 23 patients with CF (mean age
28 years, median age 25.5, range 15 to 52 years, 14 female,
9 male), for pulmonary exacerbations associated with Bcc
complex. Themean dose was 4 g/day, (range 2–6 g/day), and
the mean duration of therapy 14 days (range 1–40). A total of
six courses in three patients were eliminated from the study.
Five courses were eliminated because of insufficient data and
in one patient the antibiotic was changed due to a rash.
The study therefore included 32 courses given to 20
patients over a ten year period.
B. cepacia complex was isolated from all pre-treatment
sputum samples. The samples were cultured on plate and
susceptibility was measured on disk. The Joan Stokes method
was used to measure resistance. Unfortunately genotyping of
these strains was not available at that time. Twelve patients
were also infected with P. aeruginosa. One of these patients
received a total of three courses, and was not infected with P.
aeruginosa during the first course but was infected during the
subsequent two courses. A patient who received three
courses of temocillin also grew P. aeruginosa during the
second and third course. One patient who received four
courses cultured P. aeruginosa during the final course only.
Eight patients were infected with other organisms. These
included Staphylococcus aureus, Haemophilus influenzae,
Aspergillus fumigatus, andMycobacterium fortuitum. Six of
these eight patients were concurrently infected with P.
aeruginosa. The case notes (medical and nursing) were
reviewed, and data collected.
2.1. Outcome criteria
Outcome was measured in terms in terms of improve-
ment, deterioration or static with no change (compared to
admission baseline) in the following three categories:
clinical and physiological parameters, inflammatory
markers. This is a retrospective study and many patients
were too ill at the time of admission for lung function tests
and had to commence treatment before blood was taken for
inflammatory markers. For these reasons data is incomplete
and statistical analysis is largely inappropriate. The study is
descriptive in nature. However, statistics using Wilcoxon
signed rank test is given for the lung function.
2.1.1. Clinical
Clinical outcome was assessed by change (compared to
admission baseline) in:
& Temperature
& Dyspnoea& Sputum volume
& Chest pain
And defined as:
Improvement; Improvement in at least three parame-
ters; Static; No change in any parameter or improve-
ment in less than three parameters; Deterioration;
Deterioration in at least three parameters or insufficient
data.
2.1.2. Physiological
Physiological outcome was assessed by change (com-
pared to admission baseline) in:
& FEV1
& FVC
& Oxygen saturation
And defined as:
Improvement: improvement in at least two parameters;
static; no change in any parameter or improvement in
less than 2 parameters; deterioration; deterioration in 2
or 3 parameters.
2.1.3. Inflammatory markers
Haematological and biochemical indices were used as
outcome measures and assessed by change, (compared to
admission baseline) in:
& White blood cell count
& Erythrocyte sedimentation rate
& C-reactive protein
And defined as for Physiological parameters.
2.2. Overall outcome
2.2.1. Improvement
If improvement occurred in at least two categories
(Clinical, Physiological or Inflammatory markers).
2.2.2. Partial response
If improvement in one category, and static in the
remaining two categories.
2.2.3. Treatment failure
Static or deterioration in all categories or improve-
ment in one category and deterioration in the remaining
two.
2.2.4. Insufficient data
Designated if data was missing in two or more
categories.
Fig. 1. Results in each category.
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recorded. Outcome in terms of mortality and the timing of
the need of the next course of i.v antibiotics were recorded.3. Results
Improvement occurred in 18 (56.25%) of 32 courses of
temocillin given to 20 patients. A partial response was seen
in two courses (6.25%) and treatment failure in 12 (37.5%).
In 21 courses significant improvement was documented
in clinical parameters (dyspnoea, sputum volume produc-
tion, and chest pain). Ten were static and three deteriorated.
In four courses insufficient data was available.
In 20 courses improvement in physiological parameters
were documented (changes in FEV1, FVC, Oxygen satura-
tion). In seven courses they were static and in six they
deteriorated. An average improvement of 29.76% with a
median of 33.3%, (range 7.7–68.75%) was documented in
FEV1. An average improvement in FVC of 29.5% with a
median of 23.3% (range between 5.5% and 102%) was
identified.
Paired data were available in 19 cases for FEV1 and 18
for FVC, and the improvement was significant, 0.008 for
FEV1 and 0.0005 for FVC.
Improvement in inflammatory markers (WBC, ESR, and
CRP) occurred in 6 courses and deterioration in 4 and 2
were static. In 16 insufficient data was available (Fig. 1).
Fourteen cases showed improvement in clinical and
physiological parameters, two in a combination of clinical,
physiological and inflammatory markers, one in clinical
and inflammatory markers and one in physiological and
inflammatory markers.Fig. 2. Breakdown of response according to coThe indication for the use of temocillin was predomi-
nantly because of resistance to other antibiotics (24 out of
32 courses). Other reasons included failure of other
antibiotics (4 out of 32 courses), and intolerance to other
antibiotics (4 out of 32 courses).
Of the 18 courses given, in which the patient
improved, the average timing to the next course of i.v
antibiotics was 41.1 days (mean), 26.5 (median), and
range 8–180 days.
Two of the patients were excluded from the study
because of insufficient data, and did not require the next
course of i.v antibiotics for more than 40 days indicating a
positive response to temocillin. Improvement occurred after
13 courses of 22 in which the treatment had been given as
first line therapy and following five courses of ten given to
patients after failure of other antibiotic agents.
Eleven patients in the study received one course of i.v
temocillin, four received two courses, four received three
courses and one received four courses. During the first
course given to each of the 20 patients, 13 patients
improved, there was a partial response in one and treatment
failure in six. Of the nine patients during their second
course, three improved, there was a partial response in one,
treatment failure in three and two were excluded because of
insufficient data. Of the four patients who received three
courses; one improved, there was a treatment failure in
three, and one was excluded because of insufficient data.
One patient who received a total of four courses, improved
on three occasions, (courses 1, 2 and 4). The third course
this patient received was not included in the analysis
because of insufficient data (Fig. 2).
The mean interval between courses of temocillin was 29
weeks ranging from 3 to 66 weeks.urse of treatment of temocillin therapy.
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Eight patients died during the study; in three of these the
organism had become resistant during the course of the
study. Three of the patients died during the first course of i.v
temocillin and in two of these the bacteria were resistant to
temocillin. Two died during the second course of temocillin,
in one Bcc had become resistant to temocillin, and in
another one remained sensitive to temocillin. Both had
previously responded well to temocillin. The remaining
three patients died during the third course of temocillin. All
had previously responded well to temocillin and Bcc
isolates in sputum remained sensitive. Five of the eight
patients that died during the course of the study were
concurrently infected with P. aeruginosa.
3.2. Transplanted patients
Fourteen patients (two of the above) with Bcc were
transplanted, and if Bcc was resistant to other routine
antibiotics, they were given i.v temocillin in addition to
other antibiotics posttransplantation. Eight patients survived
(57.1%). Two died as a direct result of Bcc infection and one
of these had a temocillin resistant isolate from the sputum.
Four died of unrelated causes, (pleural bleeding, multi-organ
failure, infection and haemorrhage). In addition to the 14,
another patient developed Bcc infection in the post-
operative period, but failed to respond to i.v temocillin
and died from Bcc septicaemia.4. Discussion
Temocillin was given together with an aminoglycoside as
is usual practice in CF care. It is therefore not possible to
separate the effects of the two antibiotics which may be
synergistic. It is also known that CF patients can sometimes
respond to antibiotics to which their organism is resistant in
the laboratory.
Improvement occurred in 18 out of 32 courses of
temocillin given to 20 CF patients with acute Bcc pulmonary
infection. Although the number of the treatments and patients
is small, it seems that the clinical efficacy of temocillin is
greatest on initial use, and that subsequent reduced efficacy is
not directly linked to the emergence of resistance. The time to
the next course of intravenous antibiotics was 41 days.
Most Bcc isolates are resistant to many, or all of the
antibacterial agents commonly used in CF [5], making
successful treatment a challenge. Unfortunately genomovar
status has only recently become available. This may have
been particularly relevant to the transplantation data.
This study supports previous work from our unit [4]
which describes the successful use of temocillin in the
treatment of CF patients with both Bcc and P. aeruginosa.
In addition, we are able to present our experience of 14
patients with Bcc, who were transplanted. Encouragingly,eight patients survived, and only two deaths occurring as a
direct result of Bcc infection.
This study is a review of case notes in an area where
cases are few and a controlled trial was not possible. Many
patients were too ill for all measurements to be taken before
treatment was started. Detailed statistical analysis was
therefore not appropriate.
Temocillin is a non-toxic agent and well tolerated
enabling repeated courses to be given safely. Temocillin is
suitable for twice daily administration enhancing accept-
ability and fails to induce h-lactamase production and
therefore does not antagonise other agents given concur-
rently for concomitant P. aeruginosa infection [6]. Cross-
resistance with other h-lactam antibiotics is rarely seen [7],
and bactericidal activity in vitro is little influenced by
inoculum size [7].
Patients with Bcc may be successfully transplanted while
those with genomovar III may be more challenging [8–10].
Further controlled clinical studies comparing the use of
temocillin with other agents active against Bcc are warranted.
These findings suggest the potential benefit from i.v
temocillin in CF patients with Bcc, both for the treatment of
exacerbations and at the time of transplantation.
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